Rhabdomyosarcoma fusion oncoprotein initially pioneers a neural signature in vivo.

Autor: Kucinski J, Tallan A, Taslim C, Wang M, Cannon MV, Silvius KM, Stanton BZ, Kendall GC

Publikováno v: BioRxiv : the preprint server for biology [bioRxiv] 2024 Jul 16. Date of Electronic Publication: 2024 Jul 16.

DBD-α4 helix of EWSR1::FLI1 is required for GGAA microsatellite binding that underlies genome regulation in Ewing sarcoma.

Autor: Bayanjargal A, Taslim C, Showpnil IA, Selich-Anderson J, Crow JC, Lessnick SL, Theisen ER

Publikováno v: BioRxiv : the preprint server for biology [bioRxiv] 2024 Jun 07. Date of Electronic Publication: 2024 Jun 07.

The FLI portion of EWS/FLI contributes a transcriptional regulatory function that is distinct and separable from its DNA-binding function in Ewing sarcoma.

Autor: Boone MA; Biomedical Sciences Graduate Program, The Ohio State University, Columbus, OH, USA.; Center for Childhood Cancer and Blood Diseases, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, USA., Taslim C; Center for Childhood Cancer and Blood Diseases, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, USA., Crow JC; Center for Childhood Cancer and Blood Diseases, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, USA., Selich-Anderson J; Center for Childhood Cancer and Blood Diseases, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, USA., Byrum AK; Center for Childhood Cancer and Blood Diseases, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, USA., Showpnil IA; Center for Childhood Cancer and Blood Diseases, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, USA.; Molecular, Cellular, and Developmental Biology Graduate Program, The Ohio State University, Columbus, OH, USA., Sunkel BD; Center for Childhood Cancer and Blood Diseases, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, USA., Wang M; Center for Childhood Cancer and Blood Diseases, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, USA., Stanton BZ; Biomedical Sciences Graduate Program, The Ohio State University, Columbus, OH, USA.; Center for Childhood Cancer and Blood Diseases, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, USA.; Molecular, Cellular, and Developmental Biology Graduate Program, The Ohio State University, Columbus, OH, USA.; Department of Pediatrics, The Ohio State University, Columbus, OH, USA., Theisen ER; Biomedical Sciences Graduate Program, The Ohio State University, Columbus, OH, USA.; Center for Childhood Cancer and Blood Diseases, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, USA.; Molecular, Cellular, and Developmental Biology Graduate Program, The Ohio State University, Columbus, OH, USA.; Department of Pediatrics, The Ohio State University, Columbus, OH, USA., Lessnick SL; Biomedical Sciences Graduate Program, The Ohio State University, Columbus, OH, USA. stephen.lessnick@nationwidechildrens.org.; Center for Childhood Cancer and Blood Diseases, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, USA. stephen.lessnick@nationwidechildrens.org.; Molecular, Cellular, and Developmental Biology Graduate Program, The Ohio State University, Columbus, OH, USA. stephen.lessnick@nationwidechildrens.org.; Department of Pediatrics, The Ohio State University, Columbus, OH, USA. stephen.lessnick@nationwidechildrens.org.

Publikováno v: Oncogene [Oncogene] 2021 Jul; Vol. 40 (29), pp. 4759-4769. Date of Electronic Publication: 2021 Jun 18.

The ETS transcription factor ETV6 constrains the transcriptional activity of EWS-FLI to promote Ewing sarcoma.

Autor: Lu DY; Harvard/MIT MD-PhD Program, Harvard Medical School, Boston, MA, USA.; Department of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.; The Broad Institute of MIT and Harvard, Cambridge, MA, USA., Ellegast JM; Department of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.; The Broad Institute of MIT and Harvard, Cambridge, MA, USA., Ross KN; Department of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.; The Broad Institute of MIT and Harvard, Cambridge, MA, USA., Malone CF; Department of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.; The Broad Institute of MIT and Harvard, Cambridge, MA, USA., Lin S; Department of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.; The Broad Institute of MIT and Harvard, Cambridge, MA, USA., Mabe NW; Department of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.; The Broad Institute of MIT and Harvard, Cambridge, MA, USA., Dharia NV; Department of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.; The Broad Institute of MIT and Harvard, Cambridge, MA, USA., Meyer A; Department of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.; The Broad Institute of MIT and Harvard, Cambridge, MA, USA., Conway A; Department of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.; The Broad Institute of MIT and Harvard, Cambridge, MA, USA., Su AH; Department of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.; The Broad Institute of MIT and Harvard, Cambridge, MA, USA., Selich-Anderson J; Center for Childhood Cancer and Blood Diseases, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, USA., Taslim C; Center for Childhood Cancer and Blood Diseases, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, USA., Byrum AK; Center for Childhood Cancer and Blood Diseases, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, USA., Seong BKA; Department of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.; The Broad Institute of MIT and Harvard, Cambridge, MA, USA., Adane B; Department of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.; The Broad Institute of MIT and Harvard, Cambridge, MA, USA., Gray NS; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Rivera MN; The Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.; Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, USA., Lessnick SL; Center for Childhood Cancer and Blood Diseases, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, USA.; Division of Pediatric Hematology, Oncology and BMT, The Ohio State University College of Medicine, Columbus, OH, USA., Stegmaier K; Department of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA. Kimberly_Stegmaier@dfci.harvard.edu.; The Broad Institute of MIT and Harvard, Cambridge, MA, USA. Kimberly_Stegmaier@dfci.harvard.edu.

Publikováno v: Nature cell biology [Nat Cell Biol] 2023 Feb; Vol. 25 (2), pp. 285-297. Date of Electronic Publication: 2023 Jan 19.

Mitochondrial Dysfunction Is a Driver of SP-2509 Drug Resistance in Ewing Sarcoma.

Autor: Tokarsky EJ; Center for Childhood Cancer and Blood Diseases, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio., Crow JC; Center for Childhood Cancer and Blood Diseases, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio., Guenther LM; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts., Sherman J; Center for Childhood Cancer and Blood Diseases, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio., Taslim C; Center for Childhood Cancer and Blood Diseases, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio., Alexe G; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts., Pishas KI; Peter MacCallum Cancer Center, Melbourne, Victoria, Australia., Rask G; Center for Childhood Cancer and Blood Diseases, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio., Justis BS; Center for Childhood Cancer and Blood Diseases, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio., Kasumova A; Center for Childhood Cancer and Blood Diseases, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio., Stegmaier K; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts., Lessnick SL; Center for Childhood Cancer and Blood Diseases, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio.; Department of Pediatrics, College of Medicine, The Ohio State University, Columbus, Ohio., Theisen ER; Center for Childhood Cancer and Blood Diseases, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio.; Department of Pediatrics, College of Medicine, The Ohio State University, Columbus, Ohio.

Publikováno v: Molecular cancer research : MCR [Mol Cancer Res] 2022 Jul 06; Vol. 20 (7), pp. 1035-1046.